康艾注射液辅助治疗中晚期恶性肿瘤的临床用药评价

Effect Evaluation of Application of Kang 'ai Injection in Adjuvant Therapy of Middle-Late Malignant Tumor Treatment

目的评价康艾注射液对中晚期恶性肿瘤患者的有效性及安全性,为临床治疗提供循证参考。方法将60例中晚期恶性肿瘤患者均分为对照组和治疗组,对照组给予化疗及常规对症支持治疗,治疗组在化疗及常规对症支持治疗的基础上给予康艾注射液辅助治疗,观察2组治疗前后的近期疗效、KPS评分、临床症状、白细胞、体重及不良反应等指标。结果 2组的近期疗效、KPS评分改善、临床症状改善、白细胞变化、体重及不良反应等指标治疗前后比较,治疗组优于对照组,差异有统计学意义(P<0.05或P<0.01)。结论康艾注射液辅助治疗中晚期恶性肿瘤,有效性及安全性均更好,是一个值得临床应用的中药复方注射剂。

OBJECTIVE To evaluate the efficacy and safety of Kang’ai injection in adjuvant therapy of middle-late malignant tumor,so as to provide evidence-based reference for clinical treatment. METHODS A total of 60 patients with middle-late malignant tumor were divided into control group and treatment group,the former were given chemotherapy and conventional therapy,while the latter were given Kang’ai injection as adjuvant therapy on the basis of chemotherapy and conventional therapy. Then the indicators of the2 groups as recent curative effect,KPSscore,clinical symptoms,white blood cells,weight and adverse reactions before and after treatment were compared. RESULTS The treatment effect of patients in the treatment group is better than that of the control group according to the comparison of the indicators of the recent curative effect,KPS score,clinical symptoms,white blood cells,weight and adverse reactions before and after treatment. And the differences were statistically significant（ P〈0.05 or P〈0.01）. CONCLUSION It’s more effective and safe to use Kang’ai injection as an adjunctive therapy in the treatment of patients with middle-late malignant tumor,so it is worthy of clinical application.